Jim Simons’s Coherus Oncology CHRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $561K | Buy |
331,700
+193,800
| +141% | +$344K | ﹤0.01% | 2557 |
|
|
2025
Q4 | $196K | Buy |
137,900
+113,800
| +472% | +$166K | ﹤0.01% | 2890 |
|
|
2025
Q3 | $39.5K | Sell |
24,100
-498,825
| -95% | -$555K | ﹤0.01% | 3369 |
|
|
2025
Q2 | $382K | Buy |
522,925
+12,297
| +2% | +$10.6K | ﹤0.01% | 2962 |
|
|
2025
Q1 | $412K | Buy |
+510,628
| New | +$588K | ﹤0.01% | 2818 |
|
|
2024
Q4 | – | Sell |
-432,068
| Closed | -$449K | – | 3602 |
|
|
2024
Q3 | $449K | Buy |
432,068
+37,240
| +9% | +$51.1K | ﹤0.01% | 2836 |
|
|
2024
Q2 | $683K | Buy |
394,828
+242,500
| +159% | +$488K | ﹤0.01% | 2535 |
|
|
2024
Q1 | $364K | Buy |
+152,328
| New | +$375K | ﹤0.01% | 3002 |
|
|
2022
Q4 | – | Sell |
-52,800
| Closed | -$507K | – | 4138 |
|
|
2022
Q3 | $507K | Sell |
52,800
-152,700
| -74% | -$1.55M | ﹤0.01% | 2928 |
|
|
2022
Q2 | $1.49M | Buy |
205,500
+41,400
| +25% | +$360K | ﹤0.01% | 2418 |
|
|
2022
Q1 | $2.12M | Buy |
164,100
+108,300
| +194% | +$1.38M | ﹤0.01% | 2192 |
|
|
2021
Q4 | $891K | Buy |
+55,800
| New | +$976K | ﹤0.01% | 2736 |
|
|
2021
Q2 | – | Sell |
-230,700
| Closed | -$3.37M | – | 3486 |
|
|
2021
Q1 | $3.37M | Sell |
230,700
-30,500
| -12% | -$518K | ﹤0.01% | 1897 |
|
|
2020
Q4 | $4.54M | Buy |
261,200
+179,300
| +219% | +$3.19M | ﹤0.01% | 1657 |
|
|
2020
Q3 | $1.5M | Sell |
81,900
-324,200
| -80% | -$6.03M | ﹤0.01% | 2286 |
|
|
2020
Q2 | $7.25M | Buy |
406,100
+326,200
| +408% | +$5.52M | 0.01% | 1408 |
|
|
2020
Q1 | $1.3M | Sell |
79,900
-48,100
| -38% | -$889K | ﹤0.01% | 2293 |
|
|
2019
Q4 | $2.31M | Buy |
+128,000
| New | +$2.36M | ﹤0.01% | 2254 |
|
|
2018
Q4 | – | Sell |
-17,100
| Closed | -$282K | – | 3396 |
|
|
2018
Q3 | $282K | Buy |
+17,100
| New | +$303K | ﹤0.01% | 3039 |
|
|
2017
Q3 | – | Sell |
-21,900
| Closed | -$314K | – | 3211 |
|
|
2017
Q2 | $314K | Sell |
21,900
-91,300
| -81% | -$1.76M | ﹤0.01% | 2890 |
|
|
2017
Q1 | $2.39M | Buy |
+113,200
| New | +$2.78M | ﹤0.01% | 2141 |
|
|
2016
Q3 | – | Sell |
-94,500
| Closed | -$1.6M | – | 3338 |
|
|
2016
Q2 | $1.6M | Buy |
+94,500
| New | +$1.77M | ﹤0.01% | 2325 |
|
|
2015
Q4 | – | Sell |
-85,500
| Closed | -$1.71M | – | 3286 |
|
|
2015
Q3 | $1.71M | Buy |
85,500
+44,593
| +109% | +$1.36M | ﹤0.01% | 2096 |
|
|
2015
Q2 | $1.18M | Buy |
+40,907
| New | +$1.03M | ﹤0.01% | 2359 |
|
Other funds holding CHRS
TGY2IT
VCM
SB
KKRC
CM
Jim Simons's CHRS Position: Q1 2026 in Review
Jim Simons increased its Coherus Oncology (CHRS) stake by 141% in Q1 2026, buying an estimated $344K and bringing the position to 331,700 shares worth $561K. The position accounts for ﹤0.01% of the portfolio, ranked #2557.
Jim Simons first reported a position in CHRS in Q2 2015 and has held it in 24 quarters since. The position peaked at $7.25M in Q2 2020. 158 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.
- Jim Simons held 331,700 shares of Coherus Oncology worth $561K as of Q1 2026.
- Jim Simons bought 193,800 Coherus Oncology shares in Q1 2026, an estimated $344K.
- Coherus Oncology made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2557 holding.
- Jim Simons first reported a position in Coherus Oncology in Q2 2015 and has held it in 24 quarters since.
- Jim Simons's Coherus Oncology position peaked at $7.25M in Q2 2020.
- 158 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.